Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Androgen receptors: prognostic and therapeutic relevance

MBCC 12

16 - 18 Jun 2010

Published: 3 Sep 2010

Views: 8242

Rating:

Save

Dr Antonio Wolff - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA

Dr Antonio Wolff of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA, speaking at the 12th Milan Breast Cancer Conference, June 2010. Androgen receptors: prognostic and therapeutic relevance. Download accompanying slides here.

Related Videos

Tackling breast cancer screening in conservative communities

Dr Ru'a Rimawi - Dana-Farber Cancer Institute, Boston, United States of America

Tackling breast cancer screening in conservative communities ( Dr Ru'a Rimawi - Dana-Farber Cancer Institute, Boston, United States of America )

Post-diagnosis diet, nutrition and cancer prognosis

Dr Doris Chan - Imperial College London, London, UK

Post-diagnosis diet, nutrition and cancer prognosis ( Dr Doris Chan - Imperial College London, London, UK )

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India

Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India ( Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India )

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India

Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India ( Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

More from ecancer